

**WHAT IS CLAIMED IS:**

1. A compound of the formula 2-hydroxy-2-methyl-N-(4-X-3-(trifluoromethyl)phenyl)-3-(perfluoroacylamino)propionamide), wherein X is nitro, cyano or halo of atomic number 9 – 35, and perfluoroacylamido is of from 2 – 3 carbon atoms and of from 0 – 1 hydrogen atom.
2. A compound according to Claim 1 of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoroacetyl-amino)propionamide).
3. A compound according to Claim 1 of the formula 2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-(perfluoropropionyl-amino)propionamide).
4. A method of treating symptoms of at least one of androgenic effluvium and alopecia in a host, said method comprising:  
topically administering to said host a therapeutically effective amount for the treatment of said androgenic effluvium or alopecia of a composition comprising a compound according to Claim 1,  
for a time sufficient to treat said androgenic effluvium or alopecia.
5. A method according to Claim 4, wherein said topically administering further comprises treatment with a second antiandrogenic agent for the treatment of androgenic effluvium or alopecia.
6. The method according to Claim 4, wherein said therapeutically effective amount is at a daily dosage in the range of about 10 – 200mg/day.
7. A method of treating symptoms of a cutaneous affliction dependent upon the suppression or elimination of androgen receptor in a host, said method comprising:  
topically administering to said host in a predetermined regimen an effective amount of a composition comprising a compound according to Claim 1 to treat said cutaneous affliction.
8. The method according to Claim 7, wherein said cutaneous affliction is a hyper-androgenic skin syndrome.
9. A cosmetic or pharmaceutical formulation comprising a compound according to Claim 1 in an amount of at least about 0.1% and a pharmacologically and/or cosmetically acceptable carrier.
10. A method for decreasing synthesis of cutaneous androgen receptors in a cell, said method comprising:

contacting said cell comprising said cutaneous androgen receptors with a compound according to Claim 1 in an amount sufficient to decrease synthesis of said cutaneous androgen receptors.

11. The method according to Claim 10, wherein said cell is a hair follicle cell.